Bank of America Securities Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)
In a report released today, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $567.00. The company’s shares opened today at $444.30.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Ahmad is an analyst with an average return of -1.9% and a 49.08% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Incyte, Sarepta Therapeutics, and PTC Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Vertex Pharmaceuticals with a $516.89 average price target, which is a 16.34% upside from current levels. In a report released on May 30, BMO Capital also reiterated a Buy rating on the stock with a $557.00 price target.
The company has a one-year high of $519.88 and a one-year low of $377.85. Currently, Vertex Pharmaceuticals has an average volume of 1.74M.
Read More on VRTX:
Disclaimer & DisclosureReport an Issue
- BMO Capital Markets Reiterates ‘Buy’ Rating on Eli Lilly Stock (LLY)
- Vertex Pharmaceuticals: Strong Buy Rating Backed by Leadership in NAV1.8 Inhibitors and Strategic Collaborations
- BMO says Eli Lilly ‘well-priced deal’ to expand presence in pain a positive
- Vertex Pharmaceuticals downgraded to Hold from Buy at Erste Group
- Vertex Pharmaceuticals Launches $4 Billion Stock Buyback
